title: Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury.
abstract: The cause of cystic fibrosis-related diabetes (CFRD) remains unknown, but cystic fibrosis transmembrane conductance regulator (CFTR) mutations contribute directly to multiple aspects of the cystic fibrosis phenotype. We hypothesized that susceptibility to islet dysfunction in cystic fibrosis is determined by the lack of functional CFTR. To address this, glycemia was assessed in CFTR null (CFTR(-/-)), C57BL/6J, and FVB/NJ mice after streptozotocin (STZ)-induced beta-cell injury. Fasting blood glucose levels were similar among age-matched non-STZ-administered animals, but they were significantly higher in CFTR(-/-) mice 4 weeks after STZ administration (288.4 +/- 97.4, 168.4 +/- 35.9, and 188.0 +/- 42.3 mg/dl for CFTR(-/-), C57BL/6J, and FVB/NJ, respectively; P < 0.05). After intraperitoneal glucose administration, elevated blood glucose levels were also observed in STZ-administered CFTR(-/-) mice. STZ reduced islets among all strains; however, only CFTR(-/-) mice demonstrated a negative correlation between islet number and fasting blood glucose (P = 0.02). To determine whether a second alteration associated with cystic fibrosis (i.e., airway inflammation) could impact glucose control, animals were challenged with Aspergillus fumigatus. The A. fumigatus-sensitized CFTR(-/-) mice demonstrated similar fasting and stimulated glucose responses in comparison to nonsensitized animals. These studies suggest metabolic derangements in CFRD originate from an islet dysfunction inherent to the CFTR(-/-) state.
authors.affiliation: Department of Pathology, University of Florida, College of Medicine, PO Box 100275, Gainesville, FL 32610, USA.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Stalvey
authors.forename: Christian
authors.initials: C
authors.lastname: Muller
authors.forename: Desmond A
authors.initials: DA
authors.lastname: Schatz
authors.forename: Clive H
authors.initials: CH
authors.lastname: Wasserfall
authors.forename: Martha L
authors.initials: ML
authors.lastname: Campbell-Thompson
authors.forename: Douglas W
authors.initials: DW
authors.lastname: Theriaque
authors.forename: Terence R
authors.initials: TR
authors.lastname: Flotte
authors.forename: Mark A
authors.initials: MA
authors.lastname: Atkinson
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003550:Cystic Fibrosis / Q000150:complications; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000172:deficiency* / Q000235:genetics; D003921:Diabetes Mellitus, Experimental / Q000209:etiology; D007249:Inflammation; D007515:Islets of Langerhans / Q000293:injuries / Q000503:physiopathology*; D007700:Kinetics; D055370:Lung Injury; D051379:Mice; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D001786:Blood Glucose; D012333:RNA, Messenger; D019005:Cystic Fibrosis Transmembrane Conductance Regulator